LONDON (Alliance News) - GlaxoSmithKline PLC said Wednesday that its HIV joint venture with Pfizer Inc and Shionogi Ltd, ViiV Healthcare Ltd, received EU marketing authorisation for its drug Triumeq.
The treatment has been granted marketing authorisation for the treatment of HIV in adults and adolescents aged 12 years or older and weighing at least 40 kilograms.
"Triumeq is a direct result of ViiV Healthcare's patient-centred approach to innovation," said Chief Executive of ViiV, Dominique Limet, in a statement. "As a company that focuses 100% on HIV, our commitment is to continue to deliver new options for care and treatment for people living with HIV."
ViiV was established by Glaxo and Pfizer in 2009, and Shionogi joined as a shareholder in October 2012.
Shares in Glaxo were trading up 0.8% at 1,466.43 pence Wednesday afternoon.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.